These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1741813)

  • 21. Fluoxetine/norfluoxetine concentrations in human milk.
    Burch KJ; Wells BG
    Pediatrics; 1992 Apr; 89(4 Pt 1):676-7. PubMed ID: 1557252
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum concentrations of fluoxetine in the clinical treatment setting.
    Lundmark J; Reis M; Bengtsson F
    Ther Drug Monit; 2001 Apr; 23(2):139-47. PubMed ID: 11294514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
    Jenike MA; Baer L; Buttolph L
    J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
    Grady TA; Pigott TA; L'Heureux F; Hill JL; Bernstein SE; Murphy DL
    Am J Psychiatry; 1993 May; 150(5):819-21. PubMed ID: 8480832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solid-phase extraction of fluoxetine and norfluoxetine from serum with gas chromatography-electron-capture detection.
    Dixit V; Nguyen H; Dixit VM
    J Chromatogr; 1991 Feb; 563(2):379-84. PubMed ID: 2056002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.
    Markovitz PJ; Stagno SJ; Calabrese JR
    Am J Psychiatry; 1990 Jun; 147(6):798-800. PubMed ID: 2188516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitive and selective liquid-chromatographic assay of fluoxetine and norfluoxetine in plasma with fluorescence detection after precolumn derivatization.
    Suckow RF; Zhang MF; Cooper TB
    Clin Chem; 1992 Sep; 38(9):1756-61. PubMed ID: 1526010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enantiomeric separation of fluoxetine and norfluoxetine in plasma and serum samples with high detection sensitivity capillary electrophoresis.
    Desiderio C; Rudaz S; Raggi MA; Fanali S
    Electrophoresis; 1999 Nov; 20(17):3432-8. PubMed ID: 10608711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct analysis of fluoxetine and norfluoxetine in plasma by gas chromatography with nitrogen-phosphorus detection.
    Fontanille P; Jourdil N; Villier C; Bessard G
    J Chromatogr B Biomed Sci Appl; 1997 May; 692(2):337-43. PubMed ID: 9188822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
    Tollefson GD; Rampey AH; Potvin JH; Jenike MA; Rush AJ; kominguez RA; Koran LM; Shear MK; Goodman W; Genduso LA
    Arch Gen Psychiatry; 1994 Jul; 51(7):559-67. PubMed ID: 8031229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoxetine treatment of obsessive compulsive disorder.
    Granet RB
    J Clin Psychiatry; 1989 Nov; 50(11):436. PubMed ID: 2808312
    [No Abstract]   [Full Text] [Related]  

  • 33. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing.
    Burke WJ; Hendricks SE; McArthur-Campbell D; Jacques D; Stull T
    Psychopharmacol Bull; 1996; 32(1):27-32. PubMed ID: 8927671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A validated enantioselective assay for the simultaneous quantitation of (R)-, (S)-fluoxetine and (R)-, (S)-norfluoxetine in ovine plasma using liquid chromatography with tandem mass spectrometry (LC/MS/MS).
    Chow TW; Szeitz A; Rurak DW; Riggs KW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(5-6):349-58. PubMed ID: 21242112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
    Hollander E; Stein DJ; DeCaria CM; Saoud JB; Klein DF; Liebowitz MR
    Biol Psychiatry; 1993 May; 33(10):747-9. PubMed ID: 8353170
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation.
    Heikkinen T; Ekblad U; Palo P; Laine K
    Clin Pharmacol Ther; 2003 Apr; 73(4):330-7. PubMed ID: 12709723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoxetine for adolescents with obsessive-compulsive disorder.
    Liebowitz MR; Hollander E; Fairbanks J; Campeas R
    Am J Psychiatry; 1990 Mar; 147(3):370-1. PubMed ID: 2309962
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluoxetine and obsessive-compulsive disorder: a naturalistic study.
    Wilcox JA
    J Psychoactive Drugs; 1990; 22(3):355-6. PubMed ID: 2286870
    [No Abstract]   [Full Text] [Related]  

  • 40. Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS/MS using supported liquid extraction.
    Li Y; Emm T; Yeleswaram S
    Biomed Chromatogr; 2011 Nov; 25(11):1245-51. PubMed ID: 21308704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.